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Abstract
Nonadherence is a common reason for treatment failure 
and treatment resistance. No matter how it is defined, it is a 
major issue in the management of chronic illnesses. There 
are numerous methods to assess adherence, each with its 
own strengths and weaknesses; however, no single method 
is considered the best. Nonadherence is common in patients 
with hypertension, and it is present in a large proportion of 
patients with uncontrolled blood pressure taking three or 
more antihypertensive agents. Availability of procedure-based 
treatment options for these patients has shed further light 
on this important issue with development of new methods 
to assess adherence. There is, however, no consensus on the 
management of nonadherence, which reflects the complex 
interplay of factors responsible for it.
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Introduction
The treatment of most chronic illnesses is often characterised 
by long-term pharmacological interventions, which have been 
shown to be effective through a series of rigorous clinical 
trials. These pharmacological interventions are only effective 
if patients follow medical advice on the prescribed treatment 
regimen. Suboptimal or nonadherence is common; on 
average, around 50% of all prescribed medications for chronic 
conditions are not taken as prescribed.1,2 Nonadherence has 
serious health and socioeconomic implications.
Adherence to medications is associated with improved health 
benefits and patient outcomes. A meta-analysis has shown 
that adherence to prescribed beneficial medication, including 
a placebo, is associated with significantly lower mortality 
compared with suboptimal adherence.3
Nonadherence puts an enormous cost burden on the health 
service through medication wastage. A report of a study 
commissioned by the Department of Health, UK, in 2010 
estimated the cost of National Health Service primary and 
community care prescription medicines wastage in England 
to be £300 million per year and that for antihypertensive 
medication to be at least £100 million a year.4
There is no consistency on how medication adherence 
is reported in the literature.5 Adherence can be reported 
qualitatively as patient being adherent or nonadherent, 
which will depend on the method used to assess adherence. 
Medication adherence percentage is a common quantitative 
measure used. It is defined as the percentage of number of pills 
taken during a certain period in respect of the number of pills 
prescribed by a clinician during the same period.6
There is no consensus on the threshold to define adherence 
and nonadherence. Traditionally, a cut-off value of 80% has 
been used to dichotomise adherence; healthcare usage and 
costs in many chronic conditions including hypertension, 
diabetes, hyperlipidaemia, and schizophrenia are noted to 
be reduced in patients where medication adherence exceeds 
80%.7–11 In hypertension consumption, >80% of the prescribed 
medications have been shown to maintain blood pressure 
control.12
In this article, we have reviewed medication nonadherence 
in chronic health conditions with particular reference to 
treatment-resistant hypertension (TRH).
Medication adherence in  
clinical trials
Achievement of optimal adherence in a randomised controlled 
trial is important. Level of adherence influences the magnitude 
of observed treatment effect; greater adherence increases the 
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effect size, and poor adherence may fail to distinguish the two 
treatments. Furthermore, nonadherence to a treatment with 
worse adverse effects profile may falsely prove to be of similar 
safety when compared to treatment with a favourable adverse 
effects profile. Adherence is also an important indicator of 
how readily a treatment is accepted by patients. Despite its 
importance, adherence is underreported in clinical trials, with 
only 33–46% of published randomised controlled trials (RCTs) 
reporting adherence rates.5,13 On the other hand, reported 
rates of adherence are often remarkably high in these RCTs, 
resulting in potential overestimation of adherence due to 
underreporting.5,13–16 This may be related to the extra attention 
received by study patients, patient selection, and the observer 
effect altering patient behaviour.
Assessment of medication 
adherence
Numerous methods exist to assess the medication-taking 
behaviour of patients, and they are broadly classified into 
direct and indirect methods (Table 1). Direct methods include 
direct observation of medication being ingested by the 
patient, detection of a drug or its metabolite in the blood or 
urine, detection of a biological marker that is included in the 
drug formulation, and more recently automatic electronic 
monitoring of drug ingestion by incorporating a specially 
designed microchip within each dose of a drug.17 The direct 
methods provide proof that medication has been taken by the 
patient and are the most accurate measure of adherence.
Indirect measures of adherence have been the most widely used 
methods in research. These include patient interview, pill count, 
patient diary, patient questionnaire, measurement of physiological 
markers, and medication event monitoring system (MEMS).
The various measures of adherence have their strengths and 
weaknesses and may be appropriate in different situations 
(Table 1). No single measure of adherence can be classed as 
the gold standard, and a combination of measures may be 
used to maximise the accuracy.18,19 As described in the section 
on apparent TRH, a varied range of adherence measures have 
been used for the assessment of adherence in TRH with the 
direct testing of the drug or its metabolite in serum or urine 
being the commonest in the recent years. This choice is likely a 
manifestation of the healthcare setting where these studies have 
been carried out; specialist hypertension centres with access 
to sophisticated medical laboratories are able to perform these 
tests. These centres will have a larger proportion of patients with 
TRH; therefore, developing an assay to detect antihypertensive 
drugs and their metabolites is cost effective in the long run.
Prevalence of treatment-resistant 
hypertension
TRH has been defined as uncontrolled blood pressure where at 
least a diuretic and two other different classes of antihypertensive 
medications, taken at maximum tolerated doses, are unsuccessful 
in controlling clinic blood pressure to a target less than 140 
mmHg systolic and or 90 mmHg diastolic.20 The publication of 
SPRINT trial has challenged the well-established target blood 
pressures for diagnosis and treatment of hypertension.21 In light 
of its findings, the American College of Cardiology/American 
Heart Association has updated its hypertension guidelines 
with a radical change in the blood pressure targets used for 
diagnosis and treatment of hypertension; lowering the level of 
blood pressure to 130/80 mmHg also affects the definition of 
treatment-resistant hypertension.22 The American definition has 
retained the second element of the definition, which includes 
patients with controlled blood pressure taking four or more 
antihypertensive medications.
The former definition is widely used to estimate the prevalence 
of TRH with reported estimates ranging from 5 to 30%.23–28 A 
systematic review by Achelrod et al. report the pooled estimate 
of prevalence of TRH of 13.7% (95% confidence interval [CI]: 
11.19–16.24).29 Hayek et al. have illustrated that the prevalence 
of TRH can easily be manipulated depending on the stringency 
of the definition used.30 They showed that in the same 
population the prevalence dropped from 30.9% (SBP >140 
mmHg and ≥3 medications or controlled on four medications) 
to 3.4% (ensuring at least three medications are maximally 
dosed and one is diuretic).
The wide range of prevalence figures reflects the challenges 
in separating the true resistance from apparent resistance. 
Ambulatory blood pressure monitoring (ABPM) has been 
the gold standard for diagnosis of hypertension, as it helps 
to exclude white-coat hypertension. In treated hypertensive 
patients, the term white-coat effect (WCE) is used instead. 
WCE is one of the main reasons for the widely variable 
reported prevalence rates of TRH. Clinic or office blood pressure 
readings have been used in studies to estimate the prevalence 
of TRH until recently. With the increasing use of ABPM in clinical 
practice, it is now clear that white-coat effect is common in 
treated hypertensive individuals.31 Furthermore, a positive 
correlation exists between clinic blood pressure and the 
magnitude of WCE suggesting that individuals with the highest 
clinic blood pressure have the largest WCE.31,32 It is therefore 
not surprising that a large proportion of patients with TRH have 
been found to have significant WCE.27,33 De la Sierra et al. found 
that in a large Spanish registry of 68,045 treated hypertensive 
individuals, 8295 (12.2%) had TRH, of which 3113 (37.5%) had 
WCE such that their ABPM results classified them as having 
controlled blood pressure instead.27
The importance of accurately identifying patients with true 
TRH cannot be overestimated; there is growing evidence 
to suggest that these patients are at a much higher risk of 
cardiovascular events, chronic kidney disease, and death.34,35 
Daugherty et al. have shown that, after adjustment, the hazard 
ratio for developing a cardiovascular event in this population 
is 1.47 (95% CI: 1.33–1.62).34 Salles et al. found that over a 
5-year follow-up period, patients with true TRH had a 2.4-fold 
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Table 1. Different measures of adherence and their respective advantages and disadvantages.
Measure Advantages Disadvantages
Direct
Directly observed 
therapy 
Most accurate
Able to assess side effects as they appear
Resource intensive
Patients may still hide the medications in their 
mouth before discarding them
Provides Yes/No information on adherence
Measurement of 
medication or its 
metabolite in urine or 
serum
Objective Expensive assays required
May only be qualitative; i.e. Yes/No
Susceptible to abuse; i.e. mixing medications 
in urine sample
Adherence only tested at a single point in 
time
White-coat adherence occurs when patients 
know the schedule of tests
Variations in medication metabolism
Measurement of 
biological marker
Objective Expensive
Intrusive – requires collection of bodily 
specimens
Electronic microchip 
within a drug
Objective
Accurate
Can be used as a reference for other measures
Information on individual patient medication-
taking behaviour 
Expensive
Requires technical support
Indirect
Electronic medication 
monitors
Provides detailed information on pattern and 
level of adherence
Accurate
Can identify partial adherence
Often used as a standard to compare other 
measures against
Expensive
Requires technical support
Overestimation can occur where patients 
accidently or intentionally open the container
It requires medications to be removed from 
their original packaging
Prescription refill rates Can identify patients at risk for treatment failure
Provide medication-refilling pattern
Can provide accurate information in some 
healthcare systems that require verification for 
insurance purposes.
Records may be incomplete or difficult to 
access
Assumptions are made about medication-
taking behaviours
Unable to identify partial adherence
Pill count Objective and accurate
Provides information on long-term adherence
Patients can hoard or keep back medications 
to appear to be adherent or they simple forget 
to bring some or all the medications
Can be time consuming if taking numerous 
medications
Arbitrary cut-off value used to define 
nonadherence
Cannot identify medication-taking pattern
Measurement of 
clinical response or 
physiological markers
Can be simple, quick, and generally easily to 
perform such as measuring heart rate in patients 
taking beta-blockers
Other factors may affect the clinical response 
or the physiological marker
Patient questionnaires Simple, inexpensive
Provide real-time feedback
Identify belief and barriers to adherence
Validated for use
Affected by patient recall
Patients can easily distort the results
Relatively poor sensitivity and specificity
Affected by language barriers and the 
questions in the questionnaire
Patient diaries Simple
Can overcome poor recall
Can be used for children or patients with learning 
difficulties by their parents or carers, etc.
Open to manipulation by patients or their 
carers
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Direct observation has often been used as a surrogate 
marker for adherence.40,41 A sustained reduction in blood 
pressure following observed ingestion of tablets indicates 
prior nonadherence although any blood pressure reduction 
observed could be attributable to blood pressure variability, 
white-coat effect, or regression of blood pressure to the 
mean. Grassi et al. showed that 32% of patients presenting to 
emergency department with a systolic blood pressure >180 
mmHg and/or diastolic blood pressure >110 mmHg had a 
drop of least a 20 mmHg in basal systolic blood pressure and/
or a 10 mmHg reduction in basal diastolic blood pressure 
after a 30‐minute-period of rest where patients were seated 
in a comfortable and quiet room without talking or active 
listening.42 Some of these limitations can be minimised by using 
standardised and guideline-recommended blood pressure 
measurements and ABPM prior to commencing the directly 
observed therapy to exclude white-coat effect and reduce visit-
to-visit blood pressure variability and regression to the mean.41
We showed that in patients with TRH, after optimisation of 
antihypertensive therapy, exclusion of secondary causes of 
hypertension, and WCE, only half of the patients were truly 
treatment resistant.41 In nonadherent patients, the mean 24-
hour ambulatory blood pressure drop observed was 19.5/9.4 
mmHg when compared to ABPM carried out preceding the 
directly observed therapy. Although, this method makes intuitive 
sense in patients with TRH, it is resource and time intensive. 
Patients require close monitoring, as dramatic drops in blood 
pressure can often lead to symptomatic hypotension in patients.
Population studies have been able to study adherence 
rates in much larger populations.34,43 Sim et al., using 
hypertension databases of Kaiser Permanente healthcare 
system in the United States, found that amongst the 60,327 
individuals with resistant hypertension 7% were nonadherent. 
They used proportion of days covered by antihypertensives 
based on pharmacy refill data and a cut-off of 80% to 
dichotomise adherence.43 Daugherty et al. looked at 205,750 
incident patients diagnosed with hypertension; 3960 patients 
went on to develop TRH, on the basis of office blood pressure 
readings, during a median 1.5 years from initial treatment. 
Amongst the 3472 patients with TRH who had adherence 
assessed by prescription refill rate, 430 patients (12.4%) were 
nonadherent.34 Interestingly, the same authors reported 
in a separate analysis that in a cohort of 3550 TRH patients, 
treatment intensification but not medication adherence was 
significantly associated with 1-year blood pressure control.44 
A number of possible explanations have been suggested by 
the authors including clinical inertia, comorbid conditions, and 
lack of evidence to support the use of ≥3 antihypertensives 
at the time. It is possible that clinicians may be reluctant to 
intensify treatment if they are uncertain about a patient’s 
adherence; Rose et al. showed that adherent patients were 
more likely to receive treatment intensification which improved 
blood pressure control.45
(95% CI, 1.0–5.8-fold) increased risk of having a fatal or nonfatal 
cardiovascular event compared with white-coat TRH patients.33
Medication nonadherence and 
apparent treatment-resistant 
hypertension
In medicine, the term ‘resistant’ implies a condition that fails 
to respond to usual medical therapy. In hypertension, there 
are eight different classes of antihypertensive medications 
available – namely, thiazide/thiazide-like diuretics, renin 
angiotensin system inhibitors, calcium channel antagonists, 
alpha-adrenergic receptor blockers, beta-adrenergic receptor 
blockers, central vasodilators, aldosterone receptor antagonists, 
and miscellaneous. The recommended three first-line 
antihypertensive agents include calcium channel antagonists, 
renin angiotensin system inhibitors, and thiazide diuretics. 
There is emerging evidence that the preferred fourth-line 
antihypertensive agents are aldosterone receptor antagonists 
when compared with beta-adrenergic receptor blockers and 
alpha-adrenergic receptor blockers.36
Patients need to sufficiently adhere to the prescribed therapy 
for it to be considered to have failed. Therefore, assessment 
of adherence is a crucial aspect of management of patients 
with chronic conditions such as hypertension. Furthermore, 
increasing the number of antihypertensive medications 
may lead to increased risk of adverse effects and possible 
drug interactions. Medication adverse effects negatively 
impact patients’ adherence and uncertainty on the part of 
the physician as to whether or not to intensify treatment. 
This ‘clinical inertia’ is detrimental to patients with true TRH 
given the high risks of morbidity and mortality associated 
with uncontrolled blood pressure. Assessment of adherence 
may help to overcome this inertia. Studies reporting rates of 
nonadherence in patients with TRH and the methods used to 
assess adherence are summarised in Table 2.
Observational cohort or cross-sectional reports from specialist 
hypertension centres or general hospitals form the mainstay of 
studies describing the prevalence of nonadherence amongst 
TRH patients.37 Ceral et al. used liquid chromatography with 
mass spectrometry (LC–MS) to detect antihypertensive drugs 
in sera of 84 patients with apparent TRH.38 All of the evaluated 
antihypertensive drugs were present in 29 (34.5%) patients, no 
drugs were detected in the same number, and the remaining 
26 (31%) had some of their antihypertensive drugs in their sera. 
Jung et al. concluded that low adherence was the commonest 
cause of poor blood pressure control amongst 375 patients 
referred with uncontrolled blood pressure.39 After excluding 
white-coat effect, secondary causes of hypertension, and 
optimisation of antihypertensive therapy, 76 patients remained 
in whom LC–MS was carried out on urine samples. They found 
that 36 (47%) were adherent and 40 (53%) were nonadherent, of 
which 12 (30%) had complete nonadherence.
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Table 2. Summary of studies reporting rates of nonadherence and the methods used to measure adherence.
Study Definition of TRH Adherence method Sample 
size
Number 
nonadherent (%)
Daugherty et al.34 AHA/ESH/ESC Prescription refill rate – nonadherent 
if proportion of days covered was 
<80%
3472 430 (12.4)
Sim et al.43 AHA/ESH/ESC Prescription refill rate – nonadherent 
if proportion of days covered was 
<80%
60,327 4223 (7.0)
Burnier et al.47 SBP ≥140 or DBP ≥90 on ≥3 AHTs 
on two consecutive visits ≥1 
month apart
MEMS – nonadherent if <80% of days 
covered
41 21 (51.2)
Grigoryan et al.46 ABPM ≥135/85 or (≥125/75 if 
diabetic) on ≥3 AHTs
MEMS – nonadherent if taking <80% 
of all prescribed doses
69 20 (29.0)
Garg et al.68 SBP ≥140 or DBP ≥90 on ≥3 AHTs Patient interview – physician 
determines if patient is nonadherent
141 23 (16.0)
Yakovlevich et al.69 SBP ≥140 or DBP ≥90 on ≥3 AHTs Patient interview – physician 
determines if patient is nonadherent
91 9 (9.9)
Massierer et al.70 BP ≥140/90 on ≥3 AHTs incl.  
a diuretic
Self-reported questionnaire – 
nonadherent if score ≥3 on 4-item 
Morisky Medication Adherence Scale 
(MMAS-4)
86 21 (24.4)
Hameed et al.41 SBP ≥140 or DBP ≥90  
on ≥3 AHTs
Directly observed therapy (DOT) –  
≥5 mmHg reduction in mean 24-hour 
ambulatory SBP between Pre-DOT 
and DOT measurements was used to 
indicate nonadherence
50 25 (50)
Brinker et al.71 AHA/ESH/ESC Therapeutic drug monitoring – 
nonadherence defined if levels of 
≥1 AHTs below minimal detection 
limit
56 30 (53.6)
Ceral et al.38 SBP ≥150 or DBP ≥95  
on ≥3 AHTs
Serum drug level – nonadherence 
defined if levels of ≥1 AHTs below 
minimal detection limit
84 55 (65.5)
Ewen et al.72 SBP ≥140 on ≥3 AHTs incl. a 
diuretic at highest or maximally 
tolerated dose
Direct testing of plasma and/or urine – 
nonadherence defined if levels of ≥1 
AHTs below minimal detection limit 
100 48 (48.0)
Jung et al.39 Clinic BP ≥140/90 or ABPM 
≥130/80 on ≥4 AHTs
Direct testing of urine – 
nonadherence defined if levels of ≥1 
AHTs below minimal detection limit
76 40 (52.6)
Rosa et al.73 Clinic BP ≥140/90 and ABPM 
≥130/80 on ≥3 AHTs
Direct testing of blood – 
nonadherence defined if levels of ≥1 
AHTs below minimal detection limit
72 27 (37.5)
Strauch et al.74 Clinic BP ≥140/90 and ABPM 
≥130/80 on ≥3 AHTs
Direct testing of blood – 
nonadherence defined if levels of ≥1 
AHTs below minimal detection limit
339 110 (32.4)
Beaussier et al.75 SBP ≥140 or DBP ≥90 on ≥3 AHTs 
incl. a diuretic
Combination of plasma test, urine 
test, pill count, and patient interview – 
each element was given a score and a 
score of <2 defined nonadherence
164 30 (18.3)
ABPM, ambulatory blood pressure monitoring; AHA, American Heart Association; AHTs, antihypertensives; BP, blood pressure; 
DBP, diastolic blood pressure; ESC, European Society of Cardiology; ESH, European Society of hypertension; MEMS, medication 
event monitoring system; SBP, systolic blood pressure; TRH, treatment-resistant hypertension. 
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MEMS, a type of electronic adherence measure where a 
microchip integrated in the cap of the medication packaging 
records the date and time whenever it is opened, has been 
used to assess adherence in TRH patients.46,47 Grigoryan  
et al., using MEMS bottle caps, showed that pseudoresistance 
(nonadherence and WCE) was present in half of the patients 
with apparent TRH; nonadherence was present in 20 of the 
69 (29%) patients.46 Burnier et al. highlight the superiority 
of electronic devices in adherence monitoring in that the 
continuous monitoring itself can improve adherence and blood 
pressure control as well as provide the clinicians with detailed 
and objective information on patients’ medication-taking 
behaviours.47
A recent systematic review by Durand et al. summarises 24 
published studies reporting adherence in TRH patients.37 There 
was an average of 86 patients from 21 studies, the largest 
of which included 339 patients. They report a pooled mean 
nonadherence rate of 31.2%, with highest rates reported in 
studies that used direct methods testing patients’ sera or urine, 
followed by studies that used directly observed therapy (47.9 
and 44.6%, respectively). The lowest rate of nonadherence was 
found in a single study reporting on medication possession 
ratio at 3.3%. Interestingly, a more recently published study by 
Durand et al. of a primary care hypertensive cohort showed 
nonadherence estimates ranged from 20.3 to 41.1% depending 
on the assessment method used. They found a weak-to-moderate 
association between indirect and direct measures of adherence.48
Therefore, white-coat effect and suboptimal adherence are 
common causes of apparent TRH. Published research in 
this field often fails to exclude either one or both of these 
factors when reporting on the prevalence of TRH. Estimated 
prevalence of apparent TRH of 13.7% will drop taking into 
account the nonadherence rates and WCE, each estimated to 
be 31.2 and 37.5%, respectively. Only one very recent study 
systematically tested and excluded pseudoresistance and 
showed a true TRH prevalence of 3.3% (95% CI: 3.0–4.0).49 Even 
a conservative estimate of 50% pseudoresistance will bring the 
prevalence of true TRH to around 6–7% of total hypertensive 
population. The recent change in the American guideline may, 
however, increase this estimate.
Despite evidence of suggesting high rates of nonadherence 
in TRH patients, there is very little in the literature reporting 
on causes of nonadherence.37 Baseline blood pressure, age, 
gender, ethnicity, income, and other socioeconomic indicators 
have been linked to nonadherence in TRH. We and others have 
shown that pill burden is associated with nonadherence.50,51 
Reasons for nonadherence are rarely attributable to one 
single factor and are instead complex and multifactorial. The 
World Health Organization proposed model suggests the 
factors responsible for medication nonadherence can be 
categorised into five domains – social- and economic-related 
factors, health system/healthcare team-related factors, therapy-
related factors, condition-related factors, and patient-related 
factors – which apply to the hypertensive population as well.52,53
Management of nonadherence to 
antihypertensive medication
There is no proven intervention that has been shown to 
significantly improve adherence.1 It is important to have a 
careful consultation with the patient to identify and address 
the potential causes of suboptimal adherence. The risks and 
consequences of nonadherence and the resultant uncontrolled 
blood pressure should be explained using simple language and 
visual aids. Patients should be asked how they are managing 
their drugs in regards to dosing frequency, pill burden, and side 
effects. It may be necessary to change the medication regimen 
to fewer daily doses and even monotherapy, but frequent 
changes in medication regimen should be avoided. It may also 
be necessary to negotiate a reduction in the number of drugs 
aiming for a higher and more realistic blood pressure target. 
The importance and effectiveness of lifestyle modifications in 
lowering blood pressure should be emphasised.53
Up to 75% of patients with hypertension require more than one 
antihypertensive agent to achieve blood pressure control.54 
Single-pill fixed-dose combinations have been recommended, 
for patients requiring more than one antihypertensive 
agent, to help improve adherence and consequently blood 
pressure control.20,22 A meta-analysis has shown that fixed-
drug combinations improve adherence and persistence in 
hypertensive patients with nonsignificant beneficial trends in 
blood pressure and adverse effects compared with free drug 
combinations.55 A cohort study of 13,350 patients comparing 
fixed-drug with free-drug combinations also showed that 
the fixed-drug combination group had superior adherence 
rates of 70% compared to 42%, and a significantly lower risk of 
composite clinical outcomes including death or hospitalisation 
for acute myocardial infarction, heart failure, or stroke.56 More 
recently, the use of low-dose fixed triple drug combination 
antihypertensive pills has been shown to improve blood pressure 
control compared to usual care in patients with mild to moderate 
hypertension.57 This low-dose fixed-drug combination (FDC) 
treatment is being suggested as the initial therapy compared 
to the currently accepted practice of monotherapy. Apart 
from reducing pill burden, it may be associated with reduced 
adverse effects and consequently increased acceptability by 
the patients due to the lower doses of individual agents used. 
Furthermore, targeting of different pathways by different 
antihypertensive agents may improve efficacy. A pilot study has 
shown that a single-pill fixed triple drug combination achieved 
a mean reduction of 22.8/13.6 mmHg in clinic blood pressure 
and 9.3 mmHg reduction in 24-hour mean arterial pressure after 
18 weeks in 13 patients with TRH.58 Further larger studies are 
warranted in patients with TRH to assess the effectiveness of FDC 
and their impact on patients’ medication-taking behaviour. 
Self-monitoring of blood pressure, where patients monitor their 
own blood pressure at home, has been used as an intervention 
to show improvements in blood pressure 59,60 and adherence61 
Patients self-monitoring their blood pressure at home consulted 
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less often with their primary care physician who helps to bring 
the costs of self-monitoring on par with usual care.62 Self-
monitoring on its own, however, may not be enough to improve 
blood pressure control. Complex interventions, including 
systematic medication titration by doctors, pharmacists, or 
patients; education; or lifestyle counselling, in conjunction with 
self-monitoring lead to clinically significant blood pressure 
reduction, which persists for at least 12 months.63 A recent 
randomised controlled trial has shown that self-monitoring, with 
or without telemonitoring, when used by primary care physicians 
to titrate antihypertensive treatment in individuals with 
uncontrolled hypertension, significantly lowers blood pressure 
compared with titration guided by clinic readings.64 However, the 
efficacy of self-monitoring of blood pressure in lowering blood 
pressure in individuals with TRH has not yet been demonstrated.
Motivational interviewing has a robust evidence base to increase 
motivation and facilitate change across a range of health-
related behaviours. A meta-analysis of hypertension studies,65 
involving seven underpowered randomised controlled trials, 
shows that motivational interviewing has a significant effect on 
systolic blood pressure both after intervention and at follow-up. 
However, most studies had small sample sizes limiting statistical 
power, and motivational interviewing was often used as one 
component of multiple interventions. Although there is lack of 
robust evidence for its efficacy in apparent TRH, it is a low-cost, 
easy-to-administer intervention that may be tried in this situation.
A recent study suggests that repeated biochemical urine and 
serum analyses for antihypertensive agents may be used as 
a therapeutic approach to improve blood pressure control in 
nonadherent hypertensive patients. In this study, from two 
hypertension centres in Europe (UK and Czech Republic), 
discussing results of urine (UK) and serum (Czech Republic), 
antihypertensive assays with nonadherent patients resulted 
in improvements in adherence and blood pressure control – an 
average reduction of 19.5/7.5 mmHg in one centre and 32.6/17.4 
in the other.66 However, this was a retrospective study with 
unclear follow-up period, and, by the authors’ own admission, 
white-coat adherence effect could not be ruled out.
Finally, a recent randomised controlled trial tested if a 
smartphone app to increase patient engagement would 
improve medication adherence and blood pressure control in 
411 patients with uncontrolled hypertension. There was a small 
improvement in self-reported adherence in the intervention 
group, but there was no difference in the blood pressure 
control between the intervention and control groups.67
Conclusion
A large proportion of patients with apparent treatment-
resistant hypertension are nonadherent to prescribed 
treatment. Availability of urine assays for antihypertensive 
drugs and metabolites in the recent years has made it easier 
to identify nonadherence, which has significant detrimental 
consequences. However, no single management strategy 
has been shown to be effective in improving adherence in 
apparent treatment-resistant hypertension. Future research 
should focus on identifying interventions that will improve 
adherence in this group of patients.
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